Concurrent chemoradiotherapy (CCRT) is the choice of treatment for locally advanced cervical cancers; however, tumors exhibit diverse response to treatment. Early prediction of tumor response leads to individualizing treatment regimen. Response evaluation criteria in solid tumors (RECIST), the current modality of tumor response assessment, is often subjective and carried out at the first visit after treatment, which is about four months. Hence, there is a need for better predictive tool for radioresponse. Optical spectroscopic techniques, sensitive to molecular alteration, are being pursued as potential diagnostic tools. Present pilot study aims to explore the fiber-optic-based Raman spectroscopy approach in prediction of tumor response to CCRT, before taking up extensive in vivo studies. Ex vivo Raman spectra were acquired from biopsies collected from 11 normal (148 spectra), 16 tumor (201 spectra) and 13 complete response (151 CR spectra), one partial response (8 PR spectra) and one nonresponder (8 NR spectra) subjects. Data was analyzed using principal component linear discriminant analysis (PC-LDA) followed by leave-one-out cross-validation (LOO-CV). Findings suggest that normal tissues can be efficiently classified from both pre- and post-treated tumor biopsies, while there is an overlap between pre- and post-CCRT tumor tissues. Spectra of CR, PR and NR tissues were subjected to principal component analysis (PCA) and a tendency of classification was observed, corroborating previous studies. Thus, this study further supports the feasibility of Raman spectroscopy in prediction of tumor radioresponse and prospective noninvasive in vivo applications.
All Science Journal Classification (ASJC) codes
- Electronic, Optical and Magnetic Materials
- Medicine (miscellaneous)
- Atomic and Molecular Physics, and Optics
- Biomedical Engineering